NCVR - Stage 2 roll-out
From October 2023 the National Contract Value Review (NCVR) process will move into stage 2 of implementation, a key part of the national response to the Lord O’Shaughnessy review.
The scope of stage 2 remains the same - all commercial contract research within the NHS will go through the NCVR process, exclusing phase I-IIa and ATMP studies, and also studies being delivered within independent primary care centres. Work is underway within the ECMC Network (in collaboration with the HRA and involving us at WFC) to develop and pilot an appropriate NCVR process for ATMPs and early-phase trials, and the intention is that all study types currently excluded from the process will be brought into the system as soon as possible.
Stage 2 of the roll-out will incorporate:
Submission of studies must align with the submission process for regulatory review and approval.
All NHS organisations are required to accept the lead NHS organisation review outcome and iCT generated prices for studies in NCVR.
A new finance appendix for commercial model agreements must be used.
NHS organisations must accept the site-specific multipliers in the iCT.
Further info will be added once it is published - at the time of writing this the guidance has not yet been updated to incorporate stage 2.